30.21
0.51 (1.72%)
| Previous Close | 29.70 |
| Open | 29.56 |
| Volume | 597,589 |
| Avg. Volume (3M) | 349,431 |
| Market Cap | 751,356,736 |
| Price / Sales | 411.22 |
| Price / Book | 5.89 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -19.84 |
| Total Debt/Equity (MRQ) | 2.16% |
| Current Ratio (MRQ) | 21.11 |
| Operating Cash Flow (TTM) | -108.63 M |
| Levered Free Cash Flow (TTM) | -65.95 M |
| Return on Assets (TTM) | -44.72% |
| Return on Equity (TTM) | -75.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | RAPT Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 2.13 |
|
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 99.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 72.00 (HC Wainwright & Co., 138.33%) | Buy |
| 72.00 (Wells Fargo, 138.33%) | Buy | |
| Median | 60.00 (98.61%) | |
| Low | 37.00 (Leerink Partners, 22.48%) | Buy |
| Average | 60.57 (100.50%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 29.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 12 Nov 2025 | 57.00 (88.68%) | Buy | 29.40 |
| 20 Oct 2025 | 55.00 (82.06%) | Buy | 33.67 | |
| Barclays | 07 Nov 2025 | 56.00 (85.37%) | Buy | 28.86 |
| 21 Oct 2025 | 58.00 (91.99%) | Buy | 33.53 | |
| Wells Fargo | 03 Nov 2025 | 72.00 (138.33%) | Buy | 29.35 |
| 21 Oct 2025 | 48.00 (58.89%) | Buy | 33.53 | |
| Guggenheim | 27 Oct 2025 | 70.00 (131.71%) | Buy | 30.10 |
| HC Wainwright & Co. | 27 Oct 2025 | 72.00 (138.33%) | Buy | 30.10 |
| Clear Street | 21 Oct 2025 | 60.00 (98.61%) | Buy | 33.53 |
| 30 Sep 2025 | 41.00 (35.72%) | Buy | 25.79 | |
| Leerink Partners | 26 Sep 2025 | 37.00 (22.48%) | Buy | 26.38 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |